Amgen Inc. $AMGN Stock Holdings Lessened by Midwest Trust Co

Midwest Trust Co cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 77,424 shares of the medical research company’s stock after selling 1,492 shares during the period. Midwest Trust Co’s holdings in Amgen were worth $28,037,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. State Street Corp lifted its holdings in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors boosted its position in Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Geode Capital Management LLC boosted its position in Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. Finally, Norges Bank bought a new position in Amgen during the 4th quarter worth $2,164,162,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $415.21 on Monday. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $421.79. The stock has a market cap of $224.48 billion, a price-to-earnings ratio of 25.81, a PEG ratio of 3.86 and a beta of 0.41. The business has a fifty day moving average of $370.57 and a 200-day moving average of $358.99. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities analysts predict that Amgen Inc. will post 22.78 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio (DPR) is presently 62.65%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Barclays raised their target price on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research note on Friday. Robert W. Baird upped their price target on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Sanford C. Bernstein lifted their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Finally, Wells Fargo & Company boosted their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $372.39.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 over the last 90 days. 0.85% of the stock is owned by insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.